Once‑weekly HIV pill as effective as daily dose, research shows
Around 78% of people living with HIV take a daily pill to manage their infection. These drugs work by preventing HIV from multiplying.
Aug 5, 2026
0
3
Organic Chemical: lenacapavir
Medical news and research articles
International study shows once-weekly HIV pill performs as well as daily treatment
An international clinical trial led by researchers including Professor Chloe Orkin of Queen Mary University of London has shown that a once-weekly oral treatment for HIV is as effective as current leading daily therapies, ...
Jul 30, 2026
0
9
Inequality predicts pandemic outcomes better than technical readiness, study finds
Economic inequality is the clearest way to predict how countries will fare during a pandemic, a high-profile panel said Wednesday, calling for a rethink of how governments prepare for the next global health crisis.
Jul 30, 2026
0
6
HIV progress in 'real danger' as global funding plummets
The science has never been better, but political will has reached a new low: AIDS experts warned Monday that the fight against HIV was in real danger as funding fell by a fifth last year.
Jul 28, 2026
0
2
Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden
Growing up witnessing the devastating effects of HIV in her family and community in South Africa pushed Olwam Plaatjie to start using preventive HIV medications three years ago.
Jun 9, 2026
0
4
HIV in South Africa: Why rolling out a new shot will miss a critical group of men
The first shipment of Lenacapavir, a long-acting injectable that prevents HIV with two shots a year, arrived in South Africa from the United States in early April 2026. Clinical trials showed close to 100% efficacy. The rollout, ...
Jun 1, 2026
0
4
The Bangui operation: A story of blood, science and biomedical exploitation
In the early 1990s, a secret HIV vaccine research project was carried out in the Central African Republic. The project didn't yield results and was hidden for many years. Today it sheds light on debates over clinical trials, ...
May 1, 2026
0
6
Q&A: How studying two different viruses can lead to new strategies for more potent antiviral treatments
Beyond both being viruses, HIV-1 and SARS-CoV-2 don't seem to have a lot in common. HIV-1 is a retrovirus that integrates with its host's DNA for life and can be passed down from mother to child, while SARS-CoV-2 is contagious ...
Mar 30, 2026
0
4
Twice‑yearly injectable HIV regimen treatment demonstrates strong efficacy and safety in Phase 2 trial
A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral suppression and demonstrated ...
Mar 16, 2026
0
15
HIV can develop resistance to blockbuster antiviral lenacapavir—but at a cost to the virus
Long-acting antiviral medications are transforming HIV prevention and care, requiring only minimalistic dosing. But as the use of lenacapavir expands, scientists are probing a critical question: If the virus evolves resistance, ...
